Clinical Trials

70 enrolled

Prostatic Neoplasms

NCT04991480 2026-01-27

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

93 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Breast Neoplasms

NCT02286687 2026-01-02

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

150 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT05873192 2025-12-23

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

30 enrolled

Prostatic Neoplasms

NCT04982848 2025-11-18

Korea Post Marketing Surveillance (PMS) Study of Talzenna®

Not yet recruiting

600 enrolled

Breast Neoplasms

NCT05142241 2025-11-18

Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

14 enrolled

CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT03672773 2025-11-10

TRIO-US L-07

35 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT06844383 2025-10-29

TALENT

126 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT04497116 2025-10-21

TRESR

Phase 1/2 Completed

276 enrolled 33 charts

Other solid neoplasm

Advanced Solid Tumor

NCT03901469 2025-10-07

TNBC

Phase 2 Terminated

115 enrolled 31 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04678362 2025-09-22

TALASUR

50 enrolled

Carcinoma, Transitional Cell

NCT04486352 2025-09-04

EndoMAP

Phase 1/2 Recruiting

148 enrolled

Endometrial Neoplasms

NCT04756765 2025-08-17

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT06762808 2025-08-15

Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

Phase 2 Withdrawn

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT03990896 2025-08-07

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

30 enrolled

Breast Neoplasms

NCT05035745 2025-07-25

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Phase 1/2 Recruiting

63 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02912572 2025-07-10

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

106 enrolled 16 charts

Phase 3 Active not recruiting

Endometrial Neoplasms

NCT05059522 2025-06-25

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

68 enrolled

Ovarian Neoplasms

NCT05071937 2025-06-22

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

33 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05650476 2025-06-12

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

Available

Neoplasm Metastasis, Prostatic Neoplasms

NCT04740190 2025-06-11

TAC-GReD

33 enrolled

CNS

Glioblastoma, Glioma

NCT04849364 2025-05-31

PERSEVERE

Phase 2 Terminated

52 enrolled 16 charts

Other hematologic neoplasm

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05101551 2025-05-29

PARPAML

Phase 1 Recruiting

34 enrolled

Leukemia, Myeloid, Acute

NCT04337970 2025-05-28

Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

Phase 1/2 Completed

23 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03964532 2025-05-21

TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

Breast Neoplasms

NCT04332744 2025-05-11

ZZ-First

54 enrolled

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT04846478 2025-04-17

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

35 enrolled

Prostatic Neoplasms

NCT04892693 2025-04-17

Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

70 enrolled

Advanced Breast Cancer

NCT06193525 2025-02-28

FUTURE

66 enrolled

Breast Neoplasms

NCT05053854 2025-02-20

PARLuNET

Phase 1 Recruiting

EndocrineNET

Neuroendocrine Tumors

NCT04703920 2025-01-23

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

26 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT04187833 2025-01-14

Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes

8 enrolled 12 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT04819243 2025-01-03

Young-PALETTA

178 enrolled

Premenopausal HR+/HER2- Metastatic Breast Cancer

NCT04207190 2024-11-01

Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04672460 2024-09-25

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

BreastGastrointestinalGenitourinaryGynecologic

73 enrolled 18 charts

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03343054 2024-08-22

A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

28 enrolled 43 charts

Phase 1/2 Active not recruiting

Breast Neoplasms, Neoplasms

NCT03911973 2024-06-07

Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

37 enrolled

Triple Negative Breast Neoplasms

NCT06218628 2024-05-03

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Phase 1 Recruiting

MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT03148795 2024-04-05

A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

128 enrolled 25 charts